✦ LIBER ✦

Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders

✍ Scribed by J. Tack; M. Camilleri; L. Chang; W. D. Chey; J. J. Galligan; B. E. Lacy; S. Müller-Lissner; E. M. M. Quigley; J. Schuurkes; J. H. De Maeyer; V. Stanghellini

Book ID: 108606622
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 265 KB
Volume: 35
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2012.05011.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New-generation 5-HT 4 receptor agonists:

New-generation 5-HT 4 receptor agonists: potential for treatment of gastrointestinal motility disorders

✍ Manabe, Noriaki; Wong, Banny S; Camilleri, Michael 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 382 KB

Safety Profile of Tegaserod, a 5-HT4Rece

Safety Profile of Tegaserod, a 5-HT4Receptor Agonist, for the Treatment of Irritable Bowel Syndrome

✍ Dr William L. Hasler, Philip Schoenfeld 📂 Article 📅 2004 🏛 Springer International Publishing AG 🌐 English ⚖ 127 KB

The nonclinical safety profile of the 5-

The nonclinical safety profile of the 5-HT4 partial agonist, PF-04995274, supported clinical development for symptomatic treatment of Alzheimer's disease

✍ Pettersen, Betty; Harris, Peter; Steidl, Jill; Marcek, John; Mirsky, Michael; Pa 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Pharmacokinetics, safety and tolerabilit

Pharmacokinetics, safety and tolerability of PF-04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease

✍ Nicholas, Timothy; Raunig, David; Duvvuri, Sridhar; Plotka, Anna; Schwam, Elias; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 83 KB